GSK plc Reports Share Transaction
Ticker: GLAXF · Form: 6-K · Filed: Jul 2, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Jul 2, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-transaction, stock-buyback
TL;DR
GSK buying back its own shares via Merrill Lynch.
AI Summary
GSK plc announced a transaction in its own shares on July 2, 2025. The company is acting through its corporate stockbroker, Merrill Lynch International, for this transaction. This filing is a report of a foreign private issuer.
Why It Matters
This filing indicates GSK is actively managing its share capital, which can impact share price and investor perception.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of share transactions and does not present immediate financial or operational risks.
Key Players & Entities
- GSK plc (company) — Registrant
- Merrill Lynch International (company) — Corporate stockbroker
- July 2, 2025 (date) — Transaction date
FAQ
What type of transaction is GSK plc reporting?
GSK plc is reporting a transaction in its own shares.
Who is acting as GSK plc's corporate stockbroker for this transaction?
Merrill Lynch International is acting as GSK plc's corporate stockbroker.
What is the filing date of this report?
The filing date is July 2, 2025.
Is GSK plc required to file annual reports on Form 20-F or 40-F?
Yes, GSK plc indicates it files annual reports under cover of Form 20-F.
What is the principal executive office address of GSK plc?
The principal executive office address is 79 New Oxford Street, London, WC1A 1DG.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on July 2, 2025 regarding GSK plc (GLAXF).